StreetInsider.com News Articles

Wedbush Starts Abivax (ABVX) at Underperform

Tue, 24 Feb 2026 06:49:38 -0500

(Updated - February 24, 2026 6:49 AM EST)

Wedbush analyst David Nierengarten initiates coverage on Abivax (NASDAQ: ABVX) with a Underperform rating and a price target of $110.00.

The analyst comments "ABVX is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-mediated diseases (I&I). Lead program obefazimod is a first-in-class enhancer of a microRNA sequence, miR-124. Proposed mechanisms of action include inhibition of STAT3, MCP1, and various pro-inflammatory cytokines. A registrational Phase 3 program is ongoing in ulcerative colitis (UC), and the stock has rallied following early induction data and M&A speculation. We

Wedbush Starts Abivax (ABVX) at Underperform

Tue, 24 Feb 2026 06:49:38 -0500

(Updated - February 24, 2026 6:49 AM EST)

Wedbush analyst David Nierengarten initiates coverage on Abivax (NASDAQ: ABVX) with a Underperform rating and a price target of $110.00.

Wedbush Starts Abivax (ABVX) at Underperform

Tue, 24 Feb 2026 06:49:38 -0500

(Updated - February 24, 2026 6:49 AM EST)

Wedbush analyst David Nierengarten initiates coverage on Abivax (NASDAQ: ABVX) with a Underperform rating and a price target of $110.00.

Wedbush Starts Abivax (ABVX) at Underperform

Tue, 24 Feb 2026 06:49:38 -0500

(Updated - February 24, 2026 6:49 AM EST)

Wedbush analyst David Nierengarten initiates coverage on Abivax (NASDAQ: ABVX) with a Underperform rating and a price target of $110.00.

Form 6-K Abivax S.A. For: Feb 21

Mon, 23 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260223/26043193.html

Form 6-K Abivax S.A. For: Feb 21

Mon, 23 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260223/26043193.html

Form 6-K Abivax S.A. For: Feb 21

Mon, 23 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260223/26043193.html

Abivax (ABVX) Reiterated at Market Outperform by Citizens: Presented 22 Abstracts

Mon, 23 Feb 2026 04:42:58 -0500

Citizens analyst Jason Butler reiterated a Market Outperform rating and $131.00 price target on Abivax (NASDAQ: ABVX).

The analyst commented, "New obefazimod data and analyses reinforce differentiated efficacy and safety of obefazimod; we reiterate our Market Outperform rating and $131 risk-adjusted, DCF-derived price target on Abivax. Abivax presented 22 abstracts at the European Crohn's and Colitis Organization's (ECCO) annual meeting in Stockholm, Sweden. The abstracts highlighted additional analyses from the Phase 3 ABTECT-1 and -2 trials deepening the understanding of obefazimod's mechanism of action and underscoring the differentiated safety and efficacy of obefazimod in ulcerative colitis patients. Preclinical data presented at

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Sat, 21 Feb 2026 06:00:00 -0500

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

Fri, 13 Feb 2026 11:15:00 -0500
si-local-file:///var/storage/secattach/20260213/25997433.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

Fri, 13 Feb 2026 11:15:00 -0500
si-local-file:///var/storage/secattach/20260213/25997433.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

Fri, 13 Feb 2026 11:15:00 -0500
si-local-file:///var/storage/secattach/20260213/25997433.html

Form SCHEDULE 13D/A Abivax S.A. Filed by: Sofinnova Crossover I

Wed, 14 Jan 2026 16:13:00 -0500
si-local-file:///var/storage/secattach/20260114/25850104.html

Form SCHEDULE 13D/A Abivax S.A. Filed by: Sofinnova Crossover I

Wed, 14 Jan 2026 16:13:00 -0500
si-local-file:///var/storage/secattach/20260114/25850104.html

Form SCHEDULE 13D/A Abivax S.A. Filed by: Sofinnova Crossover I

Wed, 14 Jan 2026 16:13:00 -0500
si-local-file:///var/storage/secattach/20260114/25850104.html

Guggenheim Reiterates Abivax (ABVX) at Buy, 'ABVX remains as our Best Idea'

Tue, 13 Jan 2026 06:07:04 -0500

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $175.00 price target on Abivax (NASDAQ: ABVX).
The analyst commented: "Yesterday, we hosted an investor dinner with Abivax's management team. Key takeaways are: (1) M&A Discussion: Multiple media reports suggest that LLY (covered by Seamus Fernandez) has approached the French authorities regarding a potential M&A transaction. By around March, following ABVX’s next DSMB meeting, additional safety data should better inform any strategic pharma decision, as companies typically prefer complete safety data before finalizing a mega deal; (2) 44-week maintenance readout remains on-track for end of 2Q26 (June timeframe, per mgmt) - management